Board of directors

Carole Sable, M.D.

Member of the board of directors

Nationality: American | Year of Birth: 1961

Dr. Carole Sable has been a member of the board since April 2023. She is also a member of the corporate governance & nomination committee. She is independent in accordance with the Swiss Code of Best Practice for Corporate Governance.

Dr. Sable is an independent consultant in drug development and portfolio strategy. She has more than 30 years of experience in the field of infectious diseases, both as a physician and in senior positions in the pharmaceutical industry. From 1993 to 1995, she was assistant professor of internal medicine, infectious diseases at the University of Virginia Health Sciences Center, Charlottesville. From 1995 to 2007 and from 2010 to 2013, she worked at Merck & Co in the US in different functions including executive director, clinical research, infectious diseases and neurosciences and as vice president, therapeutic area development lead, neuroscience. She served as chief medical officer of Novexel SA (France) from 2007 to 2010, of Scynexis
Inc. (US) from 2014 to 2015, of Revolution Medicines
Inc. (US) from 2015 to 2016 and of Vitae Pharmaceuticals Inc. (US) in 2016. From 2018 to 2021, she was head of clinical development at Antabio SA (France).

Dr. Sable acts as a scientific advisor to CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and to GARDP (Global Antibiotic Research & Development Partnership).

Dr. Sable holds a bachelor of science in biology from the University of Scranton and a doctorate of medicine from the Jefferson Medical College, Philadelphia. She completed her residency in internal medicine and fellowship in infectious diseases at the University of Virginia.